STOCK TITAN

Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Smith+Nephew (NYSE:SNN) has announced the launch of its Q-FIX KNOTLESS All-Suture Anchor, expanding its portfolio for soft tissue-to-bone fixation across shoulder, hip, and foot & ankle applications. The new product builds upon the company's successful Q-FIX Family line, offering market-leading fixation strength and ultra-low displacement compared to competitive devices.

Key features include consistent deployment, best-in-class soft tissue security with a suture lock mechanism, and streamlined suture shuttling. The anchor comes with versatile suture options, including single-loaded MINITAPE Suture Tape and ULTRABRAID #2 Suture, which is 20% stronger than its nearest competitor.

Smith+Nephew (NYSE:SNN) ha annunciato il lancio del suo Q-FIX KNOTLESS All-Suture Anchor, ampliando il proprio portafoglio per la fissazione dei tessuti molli all'osso in applicazioni su spalla, anca e piede & caviglia. Il nuovo prodotto si basa sulla linea di successo Q-FIX Family dell'azienda, offrendo una forza di fissazione leader sul mercato e uno spostamento ultra-basso rispetto ai dispositivi concorrenti.

Le caratteristiche principali includono un dispiegamento costante, una sicurezza dei tessuti molli tra le migliori della categoria grazie a un meccanismo di bloccaggio del filo, e un passaggio del filo semplificato. L'ancora è disponibile con opzioni versatili di fili, tra cui il MINITAPE Suture Tape caricabile singolarmente e l'ULTRABRAID #2 Suture, che è il 20% più resistente rispetto al concorrente più vicino.

Smith+Nephew (NYSE:SNN) ha anunciado el lanzamiento de su Q-FIX KNOTLESS All-Suture Anchor, ampliando su cartera para la fijación de tejidos blandos al hueso en aplicaciones de hombro, cadera y pie & tobillo. El nuevo producto se basa en la exitosa línea Q-FIX Family de la compañía, ofreciendo una fuerza de fijación líder en el mercado y un desplazamiento ultra bajo en comparación con dispositivos competidores.

Las características clave incluyen un despliegue consistente, la mejor seguridad en tejidos blandos de su clase gracias a un mecanismo de bloqueo de sutura, y una simplificación en el paso de la sutura. El ancla viene con opciones versátiles de suturas, incluyendo MINITAPE Suture Tape cargado individualmente y ULTRABRAID #2 Suture, que es un 20% más fuerte que su competidor más cercano.

Smith+Nephew (NYSE:SNN)Q-FIX KNOTLESS All-Suture Anchor를 출시하여 어깨, 엉덩이, 발 및 발목 부위의 연조직-뼈 고정용 포트폴리오를 확장했습니다. 이 신제품은 회사의 성공적인 Q-FIX Family 라인을 기반으로 하며, 경쟁 제품에 비해 시장 선도적인 고정 강도와 초저 변위를 제공합니다.

주요 특징으로는 일관된 배치, 봉합 고정 메커니즘을 통한 동급 최고 수준의 연조직 보안성, 그리고 간소화된 봉합 전달이 포함됩니다. 이 앵커는 단일 로드된 MINITAPE 봉합 테이프와 가장 가까운 경쟁 제품보다 20% 더 강한 ULTRABRAID #2 봉합사를 포함한 다양한 봉합 옵션을 제공합니다.

Smith+Nephew (NYSE:SNN) a annoncé le lancement de son Q-FIX KNOTLESS All-Suture Anchor, élargissant ainsi son portefeuille pour la fixation des tissus mous à l'os dans les applications d'épaule, de hanche et de pied & cheville. Ce nouveau produit s'appuie sur la gamme à succès Q-FIX Family de l'entreprise, offrant une force de fixation leader sur le marché et un déplacement ultra-faible par rapport aux dispositifs concurrents.

Les caractéristiques clés incluent un déploiement constant, une sécurité des tissus mous parmi les meilleures de sa catégorie grâce à un mécanisme de verrouillage des sutures, et un passage simplifié des sutures. L'ancre est proposée avec des options de sutures polyvalentes, notamment le MINITAPE Suture Tape à chargement unique et l'ULTRABRAID #2 Suture, qui est 20 % plus résistant que son concurrent le plus proche.

Smith+Nephew (NYSE:SNN) hat die Einführung seines Q-FIX KNOTLESS All-Suture Anchor bekannt gegeben und erweitert damit sein Portfolio für die Fixierung von Weichgewebe am Knochen bei Anwendungen an Schulter, Hüfte sowie Fuß & Knöchel. Das neue Produkt baut auf der erfolgreichen Q-FIX Family Linie des Unternehmens auf und bietet marktführende Fixierungsstärke sowie ultra-geringe Verschiebung im Vergleich zu Wettbewerbsprodukten.

Zu den Hauptmerkmalen zählen eine gleichbleibende Ausbringung, erstklassige Sicherheit des Weichgewebes durch einen Knotenmechanismus und ein optimiertes Einziehen der Naht. Der Anker ist mit vielseitigen Nahtoptionen erhältlich, darunter das einzeln geladene MINITAPE Suture Tape und das ULTRABRAID #2 Suture, das 20% stärker als der nächststärkste Wettbewerber ist.

Positive
  • Market-leading strength in all-suture anchor fixation with ultra-low displacement
  • Best-in-class soft tissue security with proprietary suture lock mechanism
  • ULTRABRAID #2 Suture offers 20% greater strength versus competitors
  • Versatile application across multiple joint spaces (Shoulder, Hip, Foot & Ankle)
Negative
  • None.

Insights

Smith+Nephew's new Q-FIX KNOTLESS anchor strengthens their orthopedic portfolio with superior fixation features that should drive market share gains.

Smith+Nephew has expanded its orthopedic fixation portfolio with the Q-FIX KNOTLESS All-Suture Anchor, a specialized device for attaching soft tissue to bone across shoulder, hip, and foot/ankle applications. This product builds upon their established Q-FIX family, which already enjoys strong clinical reputation.

The technical advantages highlighted in the release are meaningful in clinical practice. The market-leading fixation strength and ultra-low displacement characteristics directly address surgeon priorities in joint repair procedures. These performance metrics correlate with reduced failure rates and improved healing outcomes in soft tissue repairs like rotator cuff procedures - a high-volume orthopedic surgery segment.

Strategically, this launch represents Smith+Nephew's continued focus on the high-margin sports medicine segment. The all-suture anchor market has seen significant growth as surgeons increasingly prefer minimally invasive approaches requiring smaller drill holes. Smith+Nephew is clearly positioning against competitive offerings from Arthrex, Stryker, and J&J/DePuy Synthes with specific benchmarking claims.

The endorsement from Dr. Litchfield highlights the reliability factor - critical for surgeon adoption as technical failures during procedures can be costly and damaging to outcomes. The dual-loading options with both MINITAPE and ULTRABRAID sutures provide versatility across different repair scenarios and surgeon preferences.

This incremental innovation strengthens Smith+Nephew's position in the competitive $5B+ sports medicine market where consistent product improvements are essential for maintaining market share and preserving pricing power.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle. 


Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices*, the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, including:

  • Market-leading strength in all-suture anchor fixation*1-5 and ultra-low displacement**1,6-10
  • Consistent deployment4,11,12
  • Best-in-class soft tissue security with our suture lock mechanism**
  • Streamlined suture shuttling5
  • Market-leading biomechanical performance,† 1-4,6,7 with the lowest displacement during cyclic loading‡1,3,6,7


The Q-FIX KNOTLESS All-Sutures Anchor offers a versatile range of suture options that include both single-loaded MINITAPE Suture Tape - which has a low profile and coreless design to offer a lower and more evenly distributed level of pressure13,14 or ULTRABRAID #2 Suture that is 20% stronger than its nearest competitor.‡‡, 15 

"When I think of the Q-FIX family I think of reliability,” commented Dr. Robert Litchfield, Orthopedic Surgeon, Sports Medicine Ontario, Canada. “We know that when we put a Q-FIX Anchor in, that we can count on it - the deployment is always predictable and the pullouts are impressive. In my experience, these anchors just don't fail when we put load on them." 

For more information about the Q-FIX KNOTLESS All-Suture Anchor for shoulder repair, please visit here.

For more information about the Q-FIX KNOTLESS All-Suture Anchor for hip repair, please visit here.

- ends –

 

Media Enquiries

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

 

 

Footnotes

*As compared to competitive devices in fixation/pull-out benchtop testing. 

**As compared to the competitive device in cyclic benchtop testing.   

†As compared to competitive all-suture anchors in cyclic and fixation/pull-out benchtop testing. 

‡As demonstrated in benchtop testing; compared to competitive devices.

‡‡ As compared to competitive devices.

 

References

1. Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975.  
2. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275.  
3. Smith+Nephew 2023. Internal Report. 10090792- Revision B.  
4. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B.  
5. Smith+Nephew 2024. Internal Report. 10144423 Rev B.  
6. ArthroCare 2019. Internal Report. Anchor. P/N 49193-02 Rev B.  
7. Barber FA, et al. Arthroscopy. 2017;33(6):1113-1121. 
8. Nagra NS, et al. Bone Joint Res. 2017;6(2):82-89.  
9. Ruder JA, et al. Arthroscopy. 2019;35(7):1954-1959 e1954.  
10. Smith+Nephew 2023. Internal Report. 10090792 Rev B.  
11. ArthroCare Corporation 2016. Internal Report: P/N 49190-01 Rev.B.  
12. Smith+Nephew 2020. Internal Report. 17-5010-11.  
13. Smith+Nephew 2016.Feasability, MINITAPE Knot Stack Evaluation and Knot Security.15005268. Rev A
14. Smith + Nephew 2013.ULTRATAPE Pressure Film Testing. 15001847. Rev A.
15. Smith+Nephew 2006.USP Knot Strength, ULTRABRAID (white). ITR-2928. Rev E.

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

Forward-looking StatementsThis document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.


FAQ

What is the new Q-FIX KNOTLESS All-Suture Anchor from Smith+Nephew (NYSE:SNN)?

It's a new soft tissue-to-bone fixation device offering market-leading fixation strength and ultra-low displacement for shoulder, hip, and foot & ankle applications.

How does the Q-FIX KNOTLESS All-Suture Anchor compare to competitors?

It offers market-leading fixation strength, ultra-low displacement during cyclic loading, and includes ULTRABRAID #2 Suture that is 20% stronger than its nearest competitor.

What are the key features of Smith+Nephew's Q-FIX KNOTLESS All-Suture Anchor?

Key features include consistent deployment, best-in-class soft tissue security with suture lock mechanism, streamlined suture shuttling, and versatile suture options including MINITAPE Suture Tape and ULTRABRAID #2 Suture.

What surgical applications is the Smith+Nephew Q-FIX KNOTLESS All-Suture Anchor designed for?

The device is designed for soft tissue-to-bone fixation across multiple joint spaces, including shoulder, hip, and foot & ankle applications.
Smith & Nephew

NYSE:SNN

SNN Rankings

SNN Latest News

SNN Latest SEC Filings

SNN Stock Data

13.39B
437.85M
0.03%
8.13%
0.37%
Medical Devices
Healthcare
Link
United Kingdom
Watford